Photocure’s partner Asieris Received China NMPA’s Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)
Shanghai China, July 8, 2020 – Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today it has received Clinical Trial Approval (CTA) from China’s National Medical Products Administration (NMPA) for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira[®]), which is being developed for the non-surgical treatment of high-grade cervical dysplasia (HSIL).In